Human trials of an HIV vaccine that aims to prompt immune system responses to virus inside the body will begin in October at Atlanta's Emory University, where the vaccine was developed, The Atlanta Journal-Constitution reports. The vaccine consists of two injections of compounds crafted from HIV genes--the first primes the body to produce an antibody response to invading virus, and a second shot activates the body's natural killer cells, which attack cells infected with HIV. The clinical trials, which will involve about 30 volunteers, will begin in early October. Preliminary results aren't expected until late 2003.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














